Shares of Akebia Therapeutics Inc. (NASDAQ:AKBA) have received a consensus rating of “Buy” from the eight ratings firms that are presently covering the company. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $14.40.

A number of analysts have recently issued reports on the company. Brean Capital assumed coverage on Akebia Therapeutics in a research note on Thursday, September 29th. They issued a “buy” rating and a $18.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Akebia Therapeutics in a research note on Tuesday, August 23rd. Zacks Investment Research lowered Akebia Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, August 11th. JMP Securities reaffirmed a “market perform” rating and issued a $16.00 price target on shares of Akebia Therapeutics in a research note on Thursday, August 11th. Finally, Credit Suisse Group AG reaffirmed a “hold” rating and issued a $8.00 price target on shares of Akebia Therapeutics in a research note on Tuesday, August 9th.

Several institutional investors have recently made changes to their positions in the stock. BlackRock Fund Advisors raised its position in shares of Akebia Therapeutics by 8.2% in the second quarter. BlackRock Fund Advisors now owns 1,408,498 shares of the biopharmaceutical company’s stock valued at $10,536,000 after buying an additional 107,049 shares during the period. Nantahala Capital Management LLC raised its position in shares of Akebia Therapeutics by 507.8% in the first quarter. Nantahala Capital Management LLC now owns 1,347,326 shares of the biopharmaceutical company’s stock valued at $12,139,000 after buying an additional 1,125,652 shares during the period. Vanguard Group Inc. raised its position in shares of Akebia Therapeutics by 6.6% in the second quarter. Vanguard Group Inc. now owns 1,085,393 shares of the biopharmaceutical company’s stock valued at $8,118,000 after buying an additional 67,246 shares during the period. Perceptive Advisors LLC raised its position in shares of Akebia Therapeutics by 3.3% in the second quarter. Perceptive Advisors LLC now owns 893,600 shares of the biopharmaceutical company’s stock valued at $6,684,000 after buying an additional 28,600 shares during the period. Finally, BlackRock Institutional Trust Company N.A. raised its position in shares of Akebia Therapeutics by 0.7% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 775,035 shares of the biopharmaceutical company’s stock valued at $5,797,000 after buying an additional 5,020 shares during the period. 51.58% of the stock is currently owned by institutional investors and hedge funds.

Shares of Akebia Therapeutics (NASDAQ:AKBA) opened at 8.03 on Friday. The firm has a 50-day moving average price of $8.67 and a 200-day moving average price of $8.61. The stock’s market cap is $146.95 million. Akebia Therapeutics has a 1-year low of $7.00 and a 1-year high of $13.20.

Akebia Therapeutics (NASDAQ:AKBA) last issued its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.95) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.57) by $0.38. Equities analysts forecast that Akebia Therapeutics will post ($3.73) EPS for the current year.

About Akebia Therapeutics

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutics based on hypoxia inducible factor (HIF) biology, and the commercialization of these products for patients with serious medical needs. The Company’s segment is the business of developing and commercializing proprietary therapeutics based on HIF biology.

5 Day Chart for NASDAQ:AKBA

Receive News & Stock Ratings for Akebia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc. and related stocks with our FREE daily email newsletter.